Abstract

With the goal of suggesting dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN), herein we report the molecular docking of an initial set of 556 compounds related to the pyridinone class. Docking with multiple crystallographic structures of HIV-1 RT led to 160 potential binders of RT interacting with key amino acid residues at the enzyme’s allosteric site. Compounds selected from the docking with RT were further docked with a crystallographic structure of HIV-1 IN. A total of 31 structures had the potential to make contacts with Mg2+ ions located in a small space between DNA and IN. Interactions with Mg2+ ions are relevant because they participate in the stabilization of the IN-DNA complex. In conclusion, 31 compounds synthetically accessible are proposed as dual inhibitors of RT and IN. It is hypothesized that the suggested compounds will inhibit RT by occupying the allosteric site for NNRTIs and will inhibit the catalytic activity of IN by destabilizing the IN-DNA complex. The main perspective of this work is the synthesis and biological testing of the candidate molecules.

Highlights

  • Acquired Immune Deficiency Syndrome (AIDS) continues to be a major health problem in the world

  • With the goal of suggesting dual inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT) and integrase (IN), we report the molecular docking of an initial set of 556 compounds related to the pyridinone class

  • The different position of this side chain is due to the bulky substituent at C-5 of the pyridinone ring of R221239, as compared to the small substituent at the same C-5 position of R157208 and R165481 in Protein Data Bank (PDB) ID: 2BAN and 2B5J, respectively

Read more

Summary

Introduction

Acquired Immune Deficiency Syndrome (AIDS) continues to be a major health problem in the world. Several compounds have been developed for the treatment of patients infected with HIV-1 [2]-[7]. These compounds, based on the mechanism of action, can be classified into five major groups: CCR5 blockers, fusion inhibitors, reverse transcriptase (RT) inhibitors (that include nucleoside, NRTIs and nonnucleoside, NNRTIs), integrase (IN), and protease (PI) inhibitors [8]. We show examples of different chemical classes under development. Examples of IN inhibitors are Elvitegralvir, Raltegravir, S-1360, and L-870810 (Figure 1)

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.